TherapeuticsMD (NASDAQ:TXMD) Now Covered by StockNews.com

StockNews.com assumed coverage on shares of TherapeuticsMD (NASDAQ:TXMD) in a research note issued to investors on Wednesday. The firm set a “hold” rating on the stock.

TherapeuticsMD Price Performance

NASDAQ:TXMD opened at $1.79 on Wednesday. TherapeuticsMD has a one year low of $1.43 and a one year high of $4.35. The company’s 50-day simple moving average is $1.92 and its 200 day simple moving average is $2.11.

TherapeuticsMD (NASDAQ:TXMD) last released its quarterly earnings data on Friday, May 10th. The company reported ($0.07) earnings per share for the quarter. The firm had revenue of $0.31 million for the quarter.

Hedge Funds Weigh In On TherapeuticsMD

An institutional investor recently bought a new position in TherapeuticsMD stock. Prosperity Consulting Group LLC bought a new position in shares of TherapeuticsMD, Inc. (NASDAQ:TXMD) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 24,500 shares of the company’s stock, valued at approximately $56,000. Prosperity Consulting Group LLC owned 0.21% of TherapeuticsMD at the end of the most recent reporting period. 30.74% of the stock is owned by hedge funds and other institutional investors.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.